Conference item icon

Conference item

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

Publication status:
Published
Peer review status:
Reviewed (other)

Actions


Access Document


Publisher copy:
10.1002/art.40700

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS
Subgroup:
Botnar Research Centre
ORCID:
0000-0002-4756-663X
Kivitz, AJ More by this author
Gladman, DD More by this author
Expand authors...
Publisher:
Wiley Publisher's website
Publication date:
2018-10-15
Acceptance date:
2018-10-15
DOI:
ISSN:
2326-5205 and 2326-5191
Pubs id:
pubs:939157
URN:
uri:153b3b9a-a9c9-4cf1-af0e-3062b39e92f0
UUID:
uuid:153b3b9a-a9c9-4cf1-af0e-3062b39e92f0
Local pid:
pubs:939157
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP